News
Baird Initiates Coverage On Alkermes with Outperform Rating, Announces Price Target of $37
19 Mar 24
News, Price Target, Initiation, Analyst Ratings
A Look Into Healthcare Sector Value Stocks
11 Mar 24
News
Alkermes Q4 Adjusted EPS $0.48 Misses $0.51 Estimate, Sales $377.48M Beat $362.02M Estimate
15 Feb 24
Earnings, News
Earnings Scheduled For February 15, 2024
15 Feb 24
Earnings
Alkermes's Earnings Outlook
14 Feb 24
Earnings
Decoding 5 Analyst Evaluations For Alkermes
2 Jan 24
Analyst Ratings
B of A Securities Maintains Neutral on Alkermes, Raises Price Target to $29
2 Jan 24
News, Price Target, Analyst Ratings
Press releases
Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors
7 Mar 24
Press Releases
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024
15 Feb 24
Earnings, Press Releases
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 15, 2024
8 Feb 24
Press Releases
Alkermes to Present at the 42nd Annual J.P. Morgan Healthcare Conference
3 Jan 24
Press Releases
Alkermes Announces Topline Results From Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI® (olanzapine and samidorphan)
3 Jan 24
Press Releases